Stockreport

Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Verrica Pharmaceuticals Inc.  (VRCA) 
Last verrica pharmaceuticals inc. earnings: 3/13 07:00 am Check Earnings Report
PDF WEST CHESTER, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling [Read more]